Almotriptan Malate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Almotriptan Malate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
22
Registered trials
5
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Almotriptan Malate can convert its Small molecule drug profile and 5-HT1B receptor x 5-HT1D receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Almotriptan Malate (query alias: almotriptan) |
|---|---|
| Modality / target | Small molecule drug; 5-HT1B receptor x 5-HT1D receptor; 5-HT1B receptor agonists, 5-HT1D receptor agonists |
| Highest global status | Approved |
| Originator | Janssen Pharmaceuticals, Inc. |
| Active developers | Not disclosed |
The MCP disease footprint includes Migraine Disorders. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| JPRN-UMIN000061371 | Phase 4 | 参加者募集終了‐試験継続中/No longer recruiting | 20 | 内服２時間後の頭痛改善、頭痛消失と有害事象 |
| NCT05214001 | Phase 4 | Terminated | 8 | Pain freedom at 2 hours |
| CTR20170172 | Phase 1 | 已完成 | 12 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Single Center Randomized Open-Label Two Arm Crossover Study of Subject Productivity Improvement and Satisfaction With Migraine Treatment Using Treximet vs Usual Triptan
Phase 4; n=60; evaluation: not stated. Reported fields: Workplace Productivity and Activity Impairment Scale (WPAI).(Mean): Mean Difference (Final Values) = -1.71(95% CI, -2.92 to -0.49), P-Value = 0.007; Workplace Productivity and Activity Impairment Scale (WPAI).(Mean) = 4.15 hours (95% Confidence Interval, 2.93 - 5.36); Workplace Productivity and Activity Impairment Scale (WPAI).(Mean): Mean Difference (Final Values) = -1.71(95% CI, -2.92 to -0.49), P-Value = 0.007
Long-Term, Open-Label Safety Study of Oral Almotriptan Malate 12.5 mg in the Treatment of Migraine in Adolescents
Phase 3; n=447; evaluation: not stated. Reported fields: Headaches Pain Free at 2 hours = 3218 Number of headaches ; -; -
Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial.
Phase 3; n=866; evaluation: Positive. Reported fields: 2-hour pain-relief rate = 55.3 % ; 2-hour pain-relief rate = 72.9 % ; 2-hour pain-relief rate = 71.8 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Almotriptan Malate addresses Migraine Disorders. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2003-04-27 | Spanish multinational drugmaker Almirall has granted a license toJohnson & Johnson's Ortho-McNeil Pharmaceutical subsidiary for Axert in the USA. | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Almotriptan malate tablet and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Preparation method of anti-migraine drug almotriptan”. The milestone feed surfaced a patent-application signal described as “Method for preparing almotriptan key intermediate”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
